About
Immuno-Oncology
Areas of Focus
Categories
Gene Therapy, RNA & Peptide Therapy
Team (22)
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
4
As Collaborator
5
Total Enrollment
752
By Phase
PHASE2: 6PHASE1: 1PHASE3: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 4ACTIVE_NOT_RECRUITING: 2COMPLETED: 2TERMINATED: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT05280314Lead Sponsor
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
PHASE2Recruiting
60 participants
Started: Dec 21, 2023 · Completed: Jan 31, 2027
NCT05977907Collaborator
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
PHASE2Recruiting
15 participants
Started: Dec 14, 2023 · Completed: Oct 16, 2028
NCT05912244Collaborator
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
PHASE2Recruiting
43 participants
Started: Jun 9, 2023 · Completed: Jun 9, 2027
NCT05843448Collaborator
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
PHASE1Recruiting
30 participants
Started: Apr 19, 2023 · Completed: Dec 31, 2026
NCT05155254Lead Sponsor
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
PHASE3Active, not recruiting
407 participants
Started: May 17, 2022 · Completed: Sep 30, 2027
Locations (1)
Headquarters
Copenhagen, Denmark
Map
Loading map...